Two commonly used uveitis drugs perform similarly in NIH-funded clinical trial,

09/10/2019 11:30 AM EDT

Methotrexate was more effective than mycophenolate mofetil at treating severe forms of the eye disease

Uveitis is inflammation of the eye originating in the uvea, which includes the iris, ciliary body, and the choroid. Lesley Earl, NEI

Methotrexate and the more expensive mycophenolate mofetil performed similarly in a head-to-head clinical trial that compared the two drugs for treating noninfectious uveitis, an eye disease that accounts for up to 15% of blindness in the U. S. In cases of more severe disease, posterior uveitis and panuveitis, the international trial showed that methotrexate was more effective in controlling inflammation. Investigators published results from the trial today in the Journal of the American Medical Association. The National Eye Institute, part of the National Institutes of Health, funded the trial.

“This study gives doctors and their patients with uveitis a starting point when considering treatment beyond corticosteroids,” said lead study author Nisha Acharya, M.D., M.S., University of California, San Francisco.

Uveitis is inflammation of the eye’s blood vessel-rich middle layer of tissue called the uvea. The condition can affect the iris (anterior uveitis), ciliary body (intermediate uveitis), and choroid (posterior uveitis) parts of the eye and is often chronic. Panuveitis affects multiple areas of the uvea. Clinicians often first treat intermediate and posterior or panuveitis with oral corticosteroids like prednisone to control inflammation, but seek to quickly taper patients to a low dose and switch them to steroid-sparing drugs such as methotrexate and mycophenolate mofetil. Long-term, high-dose corticosteroid use risks serious side effects including osteoporosis, diabetes, and weight gain, and other eye problems including glaucoma and cataract. Other steroid alternatives such as biologics like adalimumab also carry serious side effects.

The First-line Antimetabolites for Steroid-sparing Treatment (FAST) Uveitis Trial enrolled and randomly assigned 216 patients with intermediate or posterior/panuveitis from India, the United States, Australia, Saudi Arabia and Mexico to methotrexate (107 participants) or mycophenolate (109 participants) treatment groups. Over six months, participants tapered to a maximum dose of 7.5 milligrams prednisone daily, while receiving either three grams oral mycophenolate daily or 25 milligrams methotrexate weekly. Participants reduced their dose, if necessary, to control adverse side effects such as nausea.

To assess control of inflammation, the research team performed clinical exams and ocular imaging in the front and back parts of the eye. They also checked visual acuity.

At six months, 67% of participants in the methotrexate group and 57% of participants in the mycophenolate group had controlled their inflammation and successfully tapered steroids. The remainder had the option to switch treatments. Differences in success rates between treatment groups were not statistically significant at six months. At 12 months, 69% of participants who had switched from mycophenolate to methotrexate achieved treatment success, whereas only 35% of those participants who switched from methotrexate to mycophenolate achieved treatment success. Of the participants who continued with their original treatments, 80% on methotrexate and 74% on mycophenolate maintained inflammatory control at 12 months.

In patients with posterior or panuveitis, the most severe forms, 74% in the methotrexate group achieved control at six months, versus 55% in the mycophenolate group, indicating that methotrexate was significantly more effective at controlling inflammation for this subtype of uveitis.

Both methotrexate and mycophenolate mofetil, which are systemic and affect multiple cell types in the body, can cause side effects such as fatigue, nausea and headaches, but serious side effects are rare. Because participants were allowed to reduce dosage to control these side-effects, few of them dropped out of the FAST study due to their inability to tolerate the medication. Total rates of adverse events were similar between the two drugs.

“Based on this head-to-head clinical trial, methotrexate is as good as or better than mycophenolate for treating uveitis. That’s important because the prior literature and a survey on treatment preferences suggests most clinicians believe the opposite. Now we have a randomized trial to provide guidance on treatment.” said Acharya. “Additionally, there’s a cost difference in the U.S. where mycophenolate to control uveitis is over five times more expensive.”

For more information about uveitis, visit https://nei.nih.gov/health/uveitis.

This study was funded through NEI, Research to Prevent Blindness, and That Man May See Foundation. Clinical trial number NCT01829295. For more information visit https://clinicaltrials.gov/ct2/show/NCT01829295.

NEI leads the federal government’s research on the visual system and eye diseases. NEI supports basic and clinical science programs to develop sight-saving treatments and address special needs of people with vision loss. For more information, visit https://www.nei.nih.gov.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH…Turning Discovery Into Health®

Reference

Rathinam SR, Gonzales JA, Thundikandy R, Kanakath A, Murugan SB, Vedhanayaki R, Lim LL, Suhler EB, Al-Dhibi HA, Doan T, Keenan J, Rao MM, Ebert CD, Nguyen HH, Kim E, Porco TC, and Acharya N. “Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial.” Published online Sept 10, 2019, JAMA.